Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
          • Financials
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • True Cost of FSHD Study
          • Clinical Trials
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • Search
  • Financials
  • Patient Library
  • Blog
  • Calendar
  • JOIN US
  • Donate
  • JOIN US
  • Donate

The FSH Society Issues Six Research Grants

Home / FSHD Research / The FSH Society Issues Six Research Grants

Posted on: Mar 24, 2014

Today, the FSH Society announced that it has awarded six grants totaling more $609,525 to new research projects. Through these studies, the FSH Society’s fellowship program aims to gain insights and achieve significant milestones into the research of FSHD, one of the most prevalent types of muscular dystrophy.

Research grants most recently awarded by the FSH Society include: 
1.    Investigating effects of PARP1 inhibitors in DUX4 expression ($89,267)
Yi-Wen Chen, D.V.M., Ph.D. – George Washington University and Children’s National Medical Center (Washington, D.C.)
A mysterious protein called DUX4 is believed to cause FSHD. The findings of the study will provide insights of the involvement of PARP1, a promoter of the DUX4 gene, in FSHD, and will have a direct impact on developing therapeutics for FSHD.

2.    Gene surgery using TALEN technology: a therapy for FSHD ($117,500)
Julie Dumonceaux, Ph.D. – Institut de Myologie, University of Paris, U974 (Inserm, Paris, France)
The approach proposed in this study – unlike other therapeutic strategies under investigation for FSHD – does not require repeated long-term administration of treatment. The benefits of this as a clinical therapy include lower cost and reduced toxicological and immunological risk. Moreover, this approach would be useful for all FSHD cases, regardless of the precise mutation or contraction involved.

3.    Protein chemistry and protein-protein interactions of DUX4 ($70,000)
Jocelyn Eidahl, Ph.D. – The Research Institute at Nationwide Children’s Hospital (Columbus, OH)
DUX4 has been identified as potential cause for FSHD, but the mechanisms by which DUX4 contributes to FSHD pathologies is unclear. The study’s hypothesis is that the DUX4 transcription factor is involved in protein-protein interactions that influence its ability to induce toxicity in muscle cells and ultimately contribute to FSHD. The study examines the functional significance of protein-protein interactions of DUX4 that are critical for DUX4 toxicity.

4.    Exploiting genome editing technology to modify and regulate the FSHD disease locus ($125,000) Supported in part by a generous gift from the FSHD Canada Foundation.
Michael Kyba, Ph.D. – Lillehei Heart Institute, University of Minnesota (Minneapolis, MN)
Recent discoveries of DNA-binding factors have opened up tremendous new possibilities in genome editing. Through the grant, this study will take advantage of and leverage an existing research program in genome editing of FSHD iPS cells, and will provide the field with valuable new tools to study the pathogenesis of FSHD, and to develop cell therapies based on corrected, isogenic, iPS cells.

5.    Microdialysis for the study of inflammatory features in FSHD ($70,000)
Giorgio Tasca, M.D. – Institute of Neurology, Catholic University School of Medicine (Rome, Italy)
The study will implement a technique that has never been applied to the study of skeletal muscle and provide a better understanding of the role of the inflammatory process in the disease, the identification of biomarkers of disease activity at single muscle level and the acquisition of information useful for the development of a targeted anti-inflammatory therapy. In the future, the new technique could be used for molecular monitoring and eventually drug administration in neuromuscular disorders.

6.    Dynamic mapping of perturbed signaling underlying FSHD ($137,798)
Peter S. Zammit, Ph.D. – King’s College London (London, England)
Results gained through the study will identify methods that could help restore muscle regeneration in FSHD, reversing muscle weakness and wasting. The research’s ultimate aim is to gain knowledge on FSHD myogenesis and inform the design of therapies for FSHD.

“These new studies represent a crucial step in the ongoing development of FSHD treatments and cures,” said Daniel Perez, President & CEO of the FSH Society. “We are thrilled to award the grants to such innovative research endeavors, which bring us closer to finding more effective treatments – and medical breakthroughs – for FSHD.”

The FSH Society fellowship program allows research programs to develop, prove successful, and ultimately to attract funding from large funding sources such as the US National Institutes of Health (NIH) and large private sources.

Adapted from PRWeb.

Share

Filed Under: FSHD Research, FSHD Society News Tagged With: biomedical research, facioscapulohumeral muscular dystrophy, FSH, FSH muscular dystrophy, FSHD, Science, scientific grants

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

Department 960
PO Box 4106
Woburn, MA 01888-4106

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by